Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
IBIO

IBIO - iBio Inc Stock Price, Fair Value and News

$2.23-0.05 (-2.19%)
Market Closed

42/100

IBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

42/100

IBIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.08

Target 3M

$2.2

Target 6M

$2.16

IBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IBIO Price Action

Last 7 days

-0.4%

Last 30 days

20.5%

Last 90 days

43.9%

Trailing 12 Months

-24.1%

IBIO RSI Chart

IBIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IBIO Valuation

Market Cap

50.1M

Price/Earnings (Trailing)

-2.49

Price/Sales (Trailing)

100.29

Price/Free Cashflow

-2.89

IBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.08

Target 3M

$2.2

Target 6M

$2.16

IBIO Fundamentals

IBIO Revenue

Revenue (TTM)

500.0K

Rev. Growth (Yr)

14.29%

IBIO Earnings

Earnings (TTM)

-20.1M

Earnings Growth (Yr)

-43.39%

Earnings Growth (Qtr)

-10.79%

IBIO Profitability

Return on Equity

-35.88%

Return on Assets

-31.34%

Free Cashflow Yield

-34.56%

IBIO Investor Care

Shares Dilution (1Y)

145.78%

Diluted EPS (TTM)

-1.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025356.3K400.0K500.0K0
2024681.8K225.0K268.8K312.5K
2023001.6M1.1M
20222.5M2.1M00
20213.0M2.4M2.0M1.5M
20201.3M1.6M1.9M2.3M
20191.3M2.0M2.1M1.7M
2018500.0K444.0K367.0K865.0K
2017522.0K394.0K381.0K459.0K
2016989.0K948.0K923.0K864.0K
20151.4M1.9M1.2M959.0K
20140205.0K616.5K1.0M
2013741.1K1.0M00
20121.1M1.3M1.3M1.1M
20110520.1K709.3K898.5K
Get all data in R, Python etc through our Historical Stock Data APIs

About iBio Inc

IBIO
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202, which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc, as well as a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.
 CEO
 WEBSITEibioinc.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES105

iBio Inc Frequently Asked Questions

IBIO is the stock ticker symbol of iBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of iBio Inc is 50.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check IBIO's fair value in chart for subscribers.

The fair value guage provides a quick view whether IBIO is over valued or under valued. Whether iBio Inc is cheap or expensive depends on the assumptions which impact iBio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IBIO.

As of Wed Jan 28 2026, IBIO's PE ratio (Price to Earnings) is -2.49 and Price to Sales (PS) ratio is 100.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IBIO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, iBio Inc has provided -0.513 (multiply by 100 for percentage) rate of return.